Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database

Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database

Abstract Analyze the adverse event (AE) signals of istradefylline based on the FAERS database. By extracting large-scale data from the FAERS database, this study used various signal quantification techniques such as ROR, PRR, BCPNN, and MGPS to calculate and evaluate the ratio and association betwee...

Full description

Bibliographic Details
Main Authors:	Ying Jiang, Rongrong Lu, Qin Zhou, Yuan Shen, Haohao Zhu
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-04-01
Series:	Scientific Reports
Subjects:	Istradefylline FAERS Real-world data analysis Adverse events Adverse drug reaction
Online Access:	https://doi.org/10.1038/s41598-024-58460-6

Similar Items

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database
by: Feng Huang, et al.
Published: (2024-03-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024-03-01)

Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
by: SHE Youjun, GUO Zihan, ZHANG Zhongwei, DU Qiong
Published: (2023-10-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
by: Yamin Shu, et al.
Published: (2023-02-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-07-01)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseResearch in context
by: Chaozheng Zhou, et al.
Published: (2023-05-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
by: Shu Tang, et al.
Published: (2022-10-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database
by: Ja-Young Han, et al.
Published: (2024-02-01)

A Standardized Dataset of a Spontaneous Adverse Event Reporting System
by: Mohammad Ali Khaleel, et al.
Published: (2022-02-01)

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)
by: Santa Cirmi, et al.
Published: (2020-03-01)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024-01-01)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
by: Chanjuan Cui, et al.
Published: (2022-08-01)

Opioids and frequency counts in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database: a quantitative view of the epidemic
by: Veronin MA, et al.
Published: (2019-08-01)

Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database
by: Yunwei Liu, et al.
Published: (2023-03-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

Identifying new safety risk of human serum albumin: a retrospective study of real-world data
by: Hui Lu, et al.
Published: (2024-01-01)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023-11-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS
by: Luyao He, et al.
Published: (2022-02-01)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)
by: Beatriz Marinho Silva Romão, et al.
Published: (2024-01-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database
by: LIANG Cuilyu, et al.
Published: (2022-11-01)